Yes @ddwn ‘first line therapy’ .... bound to get rushed through by the FDA and of course health insurers for subsidies, so a big step forward for both Mesoblast as a company and regenerative medicine as a whole
Makes you wonder what MNK have done / are doing regarding adult GVHD partnership, although I guess now that they aren’t in an exclusive arrangement the competition will be all over this with these results ? Exciting times approaching folks !
GLTAH
Ann: Day 180 Survival Outcomes In aGvHD Phase 3 Trial, page-69
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |